Unsafe
Not Aligned
Patient Risk:
High
Summary
Markedly low alignment: numerous safety-related claims about alcohol and muscle pain are unsupported by the provided FDA label text and include an unlabeled numeric risk estimate ("up to 10%"; "50%" increase) and specific patient counseling (avoid/limit alcohol) not supported by the supplied label sections.
Category Scores
Accurate Statements
Lipitor (atorvastatin) works by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action (HMG-CoA reductase inhibition; cholesterol synthesis in the liver)
Statins, including Lipitor, can cause muscle pain (myalgia).
6.1 Clinical Trial Adverse Experiences (myalgia reported); 5.1 Skeletal Muscle (myopathy/muscle aches or weakness)
Unsupported Statements
Lipitor (atorvastatin) is a cholesterol-lowering medication.
Absent from the label content provided for evaluation (no on-label claim found in supplied sections).
The risk of Lipitor-induced muscle pain increases with higher doses.
Only partially supported in the provided label excerpts; the claim is more general than the supplied support (label supports increased risk primarily in the context of interacting drugs, and dose-associated increases are not clearly stated for myalgia as a general rule).
The risk of Lipitor-induced muscle pain increases with longer treatment durations.
No duration-associated increase for muscle pain/myalgia is supported by the provided label sections.
Lipitor-induced muscle pain occurs in up to 10% of patients.
No such incidence ("up to 10%") is supported by the provided label sections.
Alcohol consumption may exacerbate Lipitor-induced muscle pain.
No alcohol-specific muscle pain exacerbation statement is supported by the provided label sections.
Patients who consumed alcohol while taking Lipitor were more likely to experience muscle pain and stiffness than those who did not drink alcohol.
No alcohol-associated comparative risk statement is supported by the provided label sections.
Moderate to heavy alcohol consumption increased the risk of statin-induced muscle pain by 50%.
No numeric risk increase related to alcohol ("50%") is supported by the provided label sections.
Alcohol can cause damage to muscle tissue, potentially exacerbating muscle pain caused by Lipitor.
No alcohol-related muscle-tissue damage mechanism is supported by the provided label sections.
Alcohol can increase inflammation in the body, potentially worsening the muscle pain and stiffness caused by Lipitor.
No alcohol-related inflammation mechanism for muscle pain is supported by the provided label sections.
Alcohol can affect how the liver processes Lipitor, potentially leading to increased levels of the medication in the bloodstream and potentially worsening muscle pain.
No alcohol pharmacokinetic interaction with atorvastatin/raising blood levels is supported by the provided label sections.
Dr. David Jenkins stated that alcohol consumption can increase the risk of statin-induced muscle pain by altering the way the body processes these medications.
Not supported by the provided FDA label content; appears as an external authority statement not present in the label.
Patients who experience muscle pain while taking Lipitor should avoid or limit alcohol consumption to minimize the risk of exacerbating the side effect.
No patient counseling instruction about avoiding/limiting alcohol for this purpose is supported by the provided label sections.
Contradictions
Important Omissions
Label-supported guidance for muscle symptoms: advise patients to report unexplained muscle pain/tenderness/weakness; consider discontinuation if markedly elevated CPK occurs or myopathy is diagnosed/suspected; describe monitoring and drug interaction risk context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple safety-related claims about alcohol and statin-associated muscle pain are not supported by the provided label text, including specific risk quantification ("up to 10%"; "50%" increase) and direct patient counseling to avoid/limit alcohol. These could mislead patients/caregivers about risk magnitude and appropriate behavior.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unlabeled alcohol–muscle-pain risk claims and numeric risk estimates; unsupported patient instruction to avoid/limit alcohol.
Suggested Improvement
Restrict muscle-pain counseling to label-supported content (risk of myopathy; report unexplained muscle pain/tenderness/weakness; discontinuation criteria; and increased risk with specific interacting drugs). Remove alcohol-specific causality/exacerbation statements unless supported by the provided label text.